In this guide
What is DHEA?
Dehydroepiandrosterone (DHEA) is an adrenal steroid and precursor that can be converted into androgens and estrogens. Oral DHEA supplements, prescription vaginal prasterone and laboratory blood concentrations are different exposures. Results from one route or clinical indication cannot be transferred to another. [1], [4]
Typical DHEA Protocols
| Source and question | Preparation | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| He 2025 · meta-analysis · 21 studies | Oral DHEA versus control in postmenopausal women | Study-specific; not pooled as one administration | Study totals varied; subgroup at least 50 mg/day | Durations varied by trial | Estradiol and testosterone increased; heterogeneity and hormone endpoints do not establish benefit |
| Sultana 2023 · cognition review · 4 randomized studies | Oral DHEA versus placebo | Administration detail varied | All included studies used 50 mg/day | Study durations varied | Only one short study was positive; overall evidence did not support cognitive benefit and risk of bias was high |
| ODS performance evidence · resistance studies | Oral DHEA versus placebo during training | Administration grouping not reported in the overview | 100 mg/day for 12 weeks or 150 mg/day for 6 of 8 weeks | Daily during each study | No significant strength, lean-mass, aerobic-capacity or testosterone benefit versus placebo |
- Exact product
- Record species, form, lot and co-ingredients.
- Each administration
- Keep amount, timing and context.
- Real endpoint
- Separate biomarker, symptom and clinical outcome.
What is it commonly used for?
Systemic DHEA is marketed for vitality, cognition, sexual function, menopause and athletic performance. A 2025 meta-analysis of 21 randomized studies in postmenopausal women found higher estradiol and testosterone concentrations, especially in subgroups receiving at least 50 mg/day. Hormone movement is not a clinical benefit. Reviews found no consistent cognitive benefit, little or no quality-of-life benefit in menopause, and increased androgenic adverse effects. NIH ODS finds no evidence of athletic-performance benefit. [1], [2], [4]
One result answers one question
How do forms and labels differ?
Oral tablets, capsules, sublingual products, creams and prescription vaginal prasterone do not provide the same exposure. A milligram amount alone does not make routes interchangeable. Record route, exact ingredient, amount per administration, daily total, third-party testing and whether the person is subject to sport rules. [4], [5]
How should the product be stored?
Follow the finished product’s label, keep it dry in its original container and away from children. Discard an expired, heat-damaged, broken-seal or untraceable product.
What does human research show?
| Question | Best direct evidence | Finding | Boundary |
|---|---|---|---|
| Efficacy | He 2025 · meta-analysis · 21 studies | Estradiol and testosterone increased; heterogeneity and hormone endpoints do not establish benefit | Specific product and population |
| Replication | Limited evidence | No universal effect established | Variable formulations |
| Universal dose? | None | Not established | Rows cannot be combined |
Keep the finished product reviewable
What are the risks and interactions?
DHEA can increase androgen and estrogen exposure. Acne, unwanted hair growth, scalp hair changes, mood or sleep changes and altered laboratory results are relevant. Pregnancy, breastfeeding, hormone-sensitive disease, unexplained bleeding, liver disease, bipolar-spectrum symptoms and concurrent hormone therapy require clinician review. DHEA is prohibited at all times in tested sport under WADA-aligned rules. [2], [3], [5], [6]
Seek prompt care for severe mood change, chest pain, fainting, neurologic symptoms, jaundice, severe allergic reaction or suspected pregnancy during hormone exposure.
What is the legal and regulatory status?
In the United States, oral DHEA is sold in supplements, while vaginal prasterone is a distinct FDA-approved prescription drug. In Canada, verify the exact product and authorized label. DHEA is prohibited at all times in WADA-governed sport; legal retail sale does not make it permitted. [6]
When should use stop?
Stop for any allergic reaction, persistent symptom worsening, unexpected laboratory result or doubt about product identity.
What should be monitored?
Define a clinical reason before exposure and record route, each amount, daily total, product lot, symptoms and all hormone-active medicines. Laboratory monitoring must be interpreted with the clinical context; chasing a DHEA-S value or a testosterone change is not evidence of benefit. Tested athletes should check the current rule and product risk before any use.
What can community experience add?
Reports can surface acne, hair changes, sleep or mood effects and mislabeled products. They cannot establish hormone safety, cancer risk or anti-doping status. No systematic current community sample was assembled, so no consensus cycle or target blood level is reported.
How do related options compare?
| Option | Main distinction |
|---|---|
| Oral DHEA supplement | Systemic precursor exposure; efficacy and quality vary |
| Vaginal prasterone | Prescription 6.5 mg vaginal product for a defined indication |
| DHEA-S blood result | Biomarker requiring clinical interpretation, not a dosing target |
Common questions
Does a higher hormone level prove benefit?
No. A biomarker change must be separated from symptoms, function and adverse effects.
Does DHEA improve memory?
Current randomized evidence does not support a consistent cognitive benefit.
Does it improve training results?
NIH ODS finds no evidence of better strength, lean mass or aerobic performance.
Is vaginal prasterone the same as an oral supplement?
No. Route, dose, regulation and indication differ.
Is DHEA allowed in tested sport?
No. It is prohibited at all times under WADA-aligned rules; athletes must check current rules.
What should be tracked?
Exact route, product, each dose, total, symptoms, laboratory plan and sport status.
Glossary
Terms for reading the evidence.
- Endpoint
- A defined result measured in a study.
- Anaphylaxis
- A potentially life-threatening systemic allergic reaction.
- Biomarker
- A biological measure that does not guarantee clinical benefit.
- Standardization
- A measured specification for a product component.
- Cross-reactivity
- Immune recognition of related proteins from different sources.
How this guide was researched
NCBI identities, publication notices, indexed abstracts and available open methods were checked. Null outcomes, mixed products, surrogate endpoints and missing details remain visible.
Research record · checked October 9, 2026
Identity: NCBI EFetch verified the indexed reviews by title, first author, journal, DOI and descendant notices. The current NIH ODS and USADA pages were read directly. No retraction or expression of concern appeared.
Boundary: pooled hormone changes were not converted into clinical benefit. Prescription vaginal exposure and oral supplement exposure remain separate.
Sport: USADA's current DHEA guidance was used; athletes must still check the rule applying on the date of use.
Explore the sources
Primary human evidence and official context.
Showing 6 sources
- 01
Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects. ↗
Systematic review and meta-analysis
Twenty-one studies found higher estradiol and testosterone; subgroup and heterogeneity analyses do not convert hormone changes into benefit.
- 02
Effect of dehydroepiandrosterone therapy on cognitive performance among postmenopausal women: a systematic review of randomized clinical trial data. ↗
Systematic review of randomized trials
Four randomized studies all used 50 mg/day; only one short study was positive, with high overall risk of bias.
- 03
Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. ↗
Systematic review and meta-analysis
Twenty-three trials and 1188 women showed no significant quality-of-life or sexual-function benefit and documented androgenic effects.
- 04
Dehydroepiandrosterone for women in the peri- or postmenopausal phase. ↗
Cochrane systematic review
Twenty-eight trials and 1273 participants found no quality-of-life benefit; androgenic adverse effects were more frequent.
- 05
Dietary Supplements for Exercise and Athletic Performance ↗
Official evidence overview
The reviewed resistance studies did not improve strength, lean mass, aerobic capacity or testosterone versus placebo.
- 06
What Should Athletes Know about DHEA? ↗
Official anti-doping guidance
DHEA is prohibited at all times and supplement labels cannot remove the anti-doping risk.
No matching sources
Try a different term or show the full list.
Editorial note
This guide separates composition, biomarker, symptom and clinical outcome. It does not turn a narrow signal into a general promise.